Please login to the form below

Not currently logged in
Email:
Password:

Baraclude

This page shows the latest Baraclude news and features for those working in and with pharma, biotech and healthcare.

BMS shares fall on nivolumab jitters despite solid Q4 results

BMS shares fall on nivolumab jitters despite solid Q4 results

Away from oncology, arthritis treatment Orencia (abatacept) rose 22 per cent to $397m despite an increasingly crowded market and with a new subcutaneous formulation driving growth, while hepatitis B treatment Baraclude

Latest news

  • BMS exits hep C, diabetes and neuroscience drug discovery BMS exits hep C, diabetes and neuroscience drug discovery

    But it pledged to continue to advance its oral anticoagulant Eliquis (apixaban); cancer drugs Sprycel (dasatinib) and Erbitux (cetuximab); Orencia (abatacept) for arthritis; hepatitis B treatment Baraclude (entecavir); and HIV drugs

  • Teva wins challenge to BMS' Baraclude patent in US Teva wins challenge to BMS' Baraclude patent in US

    US court says hepatitis B treatment’s patent is invalid. Teva has convinced a US court that the patent protection for Bristol-Myers Squibb's hepatitis B treatment Baraclude is invalid. ... The District Court of Delaware invalidated BMS' composition of

  • BMS Q4 results see earnings increase despite fall in sales BMS Q4 results see earnings increase despite fall in sales

    Leukaemia treatment Sprycel (dasatinib) posted sales of $281m, a rise of 24 per cent, and hepatitis drug Baraclude (entecavir monohydrate) rose 13 per cent to $360m.

  • BMS launches online support for hep B patients in Europe

    The programme was organised and funded by BMS, which markets hepatitis B drug Baraclude (entecavir), and will be provided as an educational service by the World Hepatitis Alliance (WHA) and The

  • Baraclude interim data issued by BMS

    Bristol-Myers Squibb (BMS) has announced 48-week data from an ongoing study of chronic hepatitis B patients with decompensated cirrhosis, in which Baraclude demonstrated greater viral suppression compared to adefovir. ... Chronic hepatitis B is a

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics